MD George A Diaz, PharmD, BCIDP Alyssa B Christensen, MD Tobias Pusch, MD Delaney Goulet, PhD Shu-Ching Chang, PhD Gary L Grunkemeier, MISM Paul A Mckelvey, MD Ari Robicsek, MS Tom French, MD Guilford T Parsons, MPH Glenn Doherty, MS Charles Laurenson, Ryan Roper, MD Jennifer Hadlock, MD, MPH Cameron J Cover, PharmD, BCPS Brent Footer, MD Philip Robinson, ARNP Mary Micikas, MD Jennifer E Marfori, Charlotte Cronenweth, Yogavedya Mukkamala, Jamie Mackiewicz, Ekra Rai, Martha Dickinson Matson, RN Jodie Davila, Justin Rueda, Reda Tipton, Heather Algren Rn, MD Brittney C Ward, MD Stephen Malkoski, MD Tyler Gluckman, PharmD Gregory B Tallman, MD Henry Arguinchona, MD Terese C Hammond, MD Steven Standaert, MD Joshua Christensen, MD, MPH Jose F Echaiz, MD, MPH Robert Choi, MD Daniel Mcclung, MD Albert Pacifico, MD Martin Fee, MD Farjad Sarafian, MD, PhD William R Berrington, MD, MPH Jason D Goldman
doi:10.1093/cid/ciab698/6352176
From an early retrospective cohort of hospitalized COVID-19 patients, remdesivir use is associated with lower mortality compared to best supportive care. The effect remains the same for the subgroup of patients requiring low flow oxygen at baseline, similar to the ACTT-1 results.
Disclaimer The manufacturer of RDV (Gilead Sciences, Inc.) and the sponsor of ACTT-1 (NIH NIAID) approved the reuse of data for this study, but was not involved in study design, data preparation, data analysis or manuscript preparation. A c c e p t e d M a n u s c r i p t
References
Cavalcanti, Zampieri, Rosa, Hydroxychloroquine with or without Azithromycin in Mild-to-Moderate Covid-19, N Engl J Med,
doi:10.1056/NEJMoa2019014Geleris, Sun, Platt, Observational Study of Hydroxychloroquine in Hospitalized Patients with Covid-19, N Engl J Med,
doi:10.1056/NEJMoa2012410Gordon, Tchesnokov, Feng, Porter, Gotte, The antiviral compound remdesivir potently inhibits RNA-dependent RNA polymerase from Middle East respiratory syndrome coronavirus, J Biol Chem,
doi:10.1074/jbc.AC120.013056Grein, Ohmagari, Shin, Compassionate Use of Remdesivir for Patients with Severe Covid-19, New England Journal of Medicine,
doi:10.1056/nejmoa2007016Holshue, Debolt, Lindquist, First Case of 2019 Novel Coronavirus in the United States, N Engl J Med. Mar,
doi:10.1056/NEJMoa2001191Olender, Perez, Go, Remdesivir for Severe Coronavirus Disease 2019 (COVID-19) Versus a Cohort Receiving Standard of Care, Clinical Infectious Diseases,
doi:10.1093/cid/ciaa1041Pan, Peto, Repurposed Antiviral Drugs for Covid-19 -Interim WHO Solidarity Trial Results, N Engl J Med,
doi:10.1056/NEJMoa2023184Rosenberg, Dufort, Udo, Association of Treatment With Hydroxychloroquine or Azithromycin With In-Hospital Mortality in Patients With COVID-19 in New York State, JAMA,
doi:10.1001/jama.2020.8630Skipper, Pastick, Engen, Hydroxychloroquine in Nonhospitalized Adults With Early COVID-19 : A Randomized Trial, Ann Intern Med,
doi:10.7326/M20-4207Spinner, Gottlieb, Criner, Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients With Moderate COVID-19: A Randomized Clinical Trial, JAMA. Sep,
doi:10.1001/jama.2020.16349Tang, Cao, Han, Hydroxychloroquine in patients with mainly mild to moderate coronavirus disease 2019: open label, randomised controlled trial, BMJ,
doi:10.1136/bmj.m1849Yao, Ye, Zhang, Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), Clin Infect Dis,
doi:10.1093/cid/ciaa237
